Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Renhe Pharmacy Co's total inventories for the quarter that ended in Jun. 2026 was ¥314 Mil. Renhe Pharmacy Co's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was ¥352 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Renhe Pharmacy Co's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was ¥2.24.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Renhe Pharmacy Co's Days Inventory for the
three
months ended in Jun. 2026 was 51.39.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Renhe Pharmacy Co's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.78.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Renhe Pharmacy Co's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.37.
Renhe Pharmacy Co (SZSE:000650) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Renhe Pharmacy Co's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Renhe Pharmacy Co's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Renhe Pharmacy Co Total Inventories Related Terms
Renhe Pharmacy Co Total Inventories Historical Data
* Premium members only.
The historical data trend for Renhe Pharmacy Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Renhe Pharmacy Co (SZSE:000650) has a Total Inventories of ¥314 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Renhe Pharmacy Co and its competitors.
Is Renhe Pharmacy Co's Total Inventories too high?
Renhe Pharmacy Co's current Total Inventories is ¥314 Mil. Overall, Renhe Pharmacy Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Renhe Pharmacy Co's Total Inventories compare to ZTS?
Renhe Pharmacy Co's Total Inventories of ¥314 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Renhe Pharmacy Co and its competitors. Renhe Pharmacy Co's current Total Inventories is ¥314 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renhe Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Renhe Pharmacy Co (SZSE:000650) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.07, compared to a current price of ¥5.39 — trading 6.3% above its estimated fair value. The current Total Inventories is ¥314 Mil. Renhe Pharmacy Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Renhe Pharmacy Co (SZSE:000650), the current Total Inventories is ¥314 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renhe Pharmacy Co (SZSE:000650) Overvalued in 2026?
Based on GuruFocus' analysis, Renhe Pharmacy Co stock appears to be overvalued.
The current stock price of ¥5.39 is trading 6.3% above its estimated GF Value™ of ¥5.07.
GuruFocus considers Renhe Pharmacy Co to be Fairly Valued.
Key valuation signals for SZSE:000650:
Total Inventories: ¥314 Mil
GF Value™: ¥5.07 vs. price of ¥5.39 (6.3% above fair value)
No single metric tells the full story. See the SZSE:000650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renhe Pharmacy Co Ltd is a China-based company engaged in the production and sale of Chinese and Western medicines, raw materials, and health-related products, including oral solid dosage forms, oral liquid dosage forms, large-volume injections, small-volume injections, external washes, liniments, suppositories, ointments, and other dosage forms of pharmaceuticals and health-related products. The company's main products include: Renhe Kelike, Youkadan series, Fuyanjie series, Da Huo Luo capsules, Shanliang eye drops, Qinghuo capsules, and Zhengwei capsules.
83GF Score
Get the complete analysis for SZSE:000650
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000650 has been successfully added to your 
